{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T22:38:04Z","timestamp":1769812684052,"version":"3.49.0"},"reference-count":29,"publisher":"Walter de Gruyter GmbH","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Mirikizumab is a monoclonal antibody that targets the human IL-23p19 and has been humanized with IgG4. It is currently under development for treating Crohn\u2019s disease and ulcerative colitis. The FDA approved mirikizumab on October 26, 2023 as a highly effective treatment for ulcerative colitis, providing patients with a new option for this chronic and debilitating inflammatory bowel disease. Millions of people worldwide suffer from ulcerative colitis, and it is crucial to induce and maintain remission. However, existing therapies may not suffice in terms of efficacy or patient tolerability. Mirikizumab demonstrated a favorable safety profile during trials, with reported adverse events aligning with anticipated outcomes in the patient group. These safety results underscore the viability of mirikizumab as a well-tolerated therapeutic option for extended use. The trials data indicated that the treatment not only swiftly alleviated symptoms but also exhibited potential for sustaining remission over an extended period. This article seeks to offer a condensed overview of the noteworthy clinical trial outcomes that contributed to the development of mirikizumab, ultimately leading to its initial approval for the treatment of ulcerative colitis.<\/jats:p>","DOI":"10.1515\/jbcpp-2024-0102","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T05:56:30Z","timestamp":1764136590000},"page":"25-31","source":"Crossref","is-referenced-by-count":0,"title":["Interleukin-23 (IL-23) inhibitor, mirikizumab in the treatment of ulcerative colitis (UC): a promising therapy?"],"prefix":"10.1515","volume":"37","author":[{"given":"Saurav","family":"Misra","sequence":"first","affiliation":[{"name":"Department of Pharmacology , Kalpana Chawla Government Medical College , Karnal , Haryana , India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manmeet","family":"Kaur","sequence":"additional","affiliation":[{"name":"Department of Pharmacology , Kalpana Chawla Government Medical College , Karnal , Haryana , India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashish Kumar","family":"Saranjhna","sequence":"additional","affiliation":[{"name":"Department of Pharmacology , Kalpana Chawla Government Medical College , Karnal , Haryana , India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"2026013012042184244_j_jbcpp-2024-0102_ref_001","doi-asserted-by":"crossref","unstructured":"Gajendran, M, Loganathan, P, Jimenez, G, Catinella, AP, Ng, N, Umapathy, C, et al.. A comprehensive review and update on ulcerative colitis. Dis Mon 2019;65:100851. https:\/\/doi.org\/10.1016\/j.disamonth.2019.02.004.","DOI":"10.1016\/j.disamonth.2019.02.004"},{"key":"2026013012042184244_j_jbcpp-2024-0102_ref_002","unstructured":"Lynch, WD, Hsu, R. Ulcerative colitis. Treasure Island (FL): StatPearls Publishing; 2023. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK459282\/."},{"key":"2026013012042184244_j_jbcpp-2024-0102_ref_003","doi-asserted-by":"crossref","unstructured":"Feuerstein, JD, Moss, AC, Farraye, FA. Ulcerative colitis. Mayo Clin Proc 2019; 94: 1357\u201373. https:\/\/doi.org\/10.1016\/j.mayocp.2019.01.018.","DOI":"10.1016\/j.mayocp.2019.01.018"},{"key":"2026013012042184244_j_jbcpp-2024-0102_ref_004","doi-asserted-by":"crossref","unstructured":"Ashton, JJ, Ennis, S, Beattie, RM. Early-onset paediatric inflammatory bowel disease. Lancet Child Adolesc Health 2017;1:147\u201358.https:\/\/doi.org\/10.1016\/s2352-4642(17)30017-2.","DOI":"10.1016\/S2352-4642(17)30017-2"},{"key":"2026013012042184244_j_jbcpp-2024-0102_ref_005","doi-asserted-by":"crossref","unstructured":"Liu, CY, Polk, DB. Microbiomes through the looking glass: what do UC? Cell Host Microbe 2018;24:472\u20134. https:\/\/doi.org\/10.1016\/j.chom.2018.09.013.","DOI":"10.1016\/j.chom.2018.09.013"},{"key":"2026013012042184244_j_jbcpp-2024-0102_ref_006","doi-asserted-by":"crossref","unstructured":"Gradel, KO, Nielsen, HL, Sch\u00f8nheyder, HC, Ejlertsen, T, Kristensen, B, Nielsen, H. Increased short- and long-term risk of inflammatory bowel disease after Salmonella or Campylobacter gastroenteritis. Gastroenterology 2009;137:495\u2013501. https:\/\/doi.org\/10.1053\/j.gastro.2009.04.001.","DOI":"10.1053\/j.gastro.2009.04.001"},{"key":"2026013012042184244_j_jbcpp-2024-0102_ref_007","doi-asserted-by":"crossref","unstructured":"Guardiola, J, Lobat\u00f3n, T, Cerrillo, E, Ferreiro-Iglesias, R, Gisbert, JP, Dom\u00e8nech, E, et al.. Recommendations of the Spanish working group on Crohn\u2019s disease and ulcerative colitis (GETECCU) on the utility of the determination of faecal calprotectin in inflammatory bowel disease. Gastroenterol Hepatol 2018;41:514\u201329. https:\/\/doi.org\/10.1016\/j.gastrohep.2018.05.029.","DOI":"10.1016\/j.gastre.2018.05.018"},{"key":"2026013012042184244_j_jbcpp-2024-0102_ref_008","doi-asserted-by":"crossref","unstructured":"Lee, JS, Kim, ES, Moon, W. Chronological review of endoscopic indices in inflammatory bowel disease. Clin Endosc 2019;52:129\u201336. https:\/\/doi.org\/10.5946\/ce.2018.042.","DOI":"10.5946\/ce.2018.042"},{"key":"2026013012042184244_j_jbcpp-2024-0102_ref_009","unstructured":"Meier, J, Sturm, A. Current treatment of ulcerative colitis. World J Gastroenterol 2011;17:3204\u201312. https:\/\/doi.org\/10.3748\/wjg.v17.i27.3204."},{"key":"2026013012042184244_j_jbcpp-2024-0102_ref_010","doi-asserted-by":"crossref","unstructured":"Ferretti, F, Cannatelli, R, Monico, MC, Maconi, G, Ardizzone, S. An update on current pharmacotherapeutic options for the treatment of ulcerative colitis. J\u00a0Clin Med 2022;11:2302. https:\/\/doi.org\/10.3390\/jcm11092302.","DOI":"10.3390\/jcm11092302"},{"key":"2026013012042184244_j_jbcpp-2024-0102_ref_011","doi-asserted-by":"crossref","unstructured":"Ungaro, R, Mehandru, S, Allen, PB, Peyrin-Biroulet, L, Colombel, JF. Ulcerative colitis. Lancet 2017;389:1756\u201370. https:\/\/doi.org\/10.1016\/s0140-6736(16)32126-2.","DOI":"10.1016\/S0140-6736(16)32126-2"},{"key":"2026013012042184244_j_jbcpp-2024-0102_ref_012","doi-asserted-by":"crossref","unstructured":"Croxford, AL, Mair, F, Becher, B. IL-23: one cytokine in control of autoimmunity. Eur J Immunol 2012;42:2263\u201373. https:\/\/doi.org\/10.1002\/eji.201242598.","DOI":"10.1002\/eji.201242598"},{"key":"2026013012042184244_j_jbcpp-2024-0102_ref_013","doi-asserted-by":"crossref","unstructured":"Croxford, AL, Kulig, P, Becher, B. IL-12-and IL-23 in health and disease. Cytokine Growth Factor Rev 2014;25:415\u201321. https:\/\/doi.org\/10.1016\/j.cytogfr.2014.07.017.","DOI":"10.1016\/j.cytogfr.2014.07.017"},{"key":"2026013012042184244_j_jbcpp-2024-0102_ref_014","doi-asserted-by":"crossref","unstructured":"Gheita, TA, El Gazzar, II, El-Fishawy, HS, Aboul-Ezz, MA, Kenawy, SA. Involvement of IL-23 in enteropathic arthritis patients with inflammatory bowel disease: preliminary results. Clin Rheumatol 2014;33:713\u20137. https:\/\/doi.org\/10.1007\/s10067-013-2469-y.","DOI":"10.1007\/s10067-013-2469-y"},{"key":"2026013012042184244_j_jbcpp-2024-0102_ref_015","doi-asserted-by":"crossref","unstructured":"Globig, AM, Hennecke, N, Martin, B, Seidl, M, Ruf, G, Hasselblatt, P, et al.. Comprehensive intestinal T helper cell profiling reveals specific accumulation of IFN-\u03b3+IL-17+coproducing CD4+ T\u00a0cells in active inflammatory bowel disease. Inflamm Bowel Dis 2014;20:2321\u20139. https:\/\/doi.org\/10.1097\/mib.0000000000000210.","DOI":"10.1097\/MIB.0000000000000210"},{"key":"2026013012042184244_j_jbcpp-2024-0102_ref_016","doi-asserted-by":"crossref","unstructured":"El-Bassat, H, AboAli, L, El Yamany, S, Al Shenawy, H, Al Din, RA, Taha, A. Interleukin-23p19 expression in patients with ulcerative colitis and its relation to disease severity. Adv Digest Med 2016;3:88\u201394. https:\/\/doi.org\/10.1016\/j.aidm.2015.04.002.","DOI":"10.1016\/j.aidm.2015.04.002"},{"key":"2026013012042184244_j_jbcpp-2024-0102_ref_017","unstructured":"Food and drug administration (FDA) [Home page in internet] FDA Approved Drug Products: Omvoh (mirikizumab-mrkz) injection for intravenous or subcutaneous administration [Last cited on 22\/11\/2025] Available from: https:\/\/investor.lilly.com\/news-releases\/news-release-details\/fda-approves-lillys-omvohtm-mirikizumab-mrkz-first-class#:\u223c:text=Omvoh%20(mirikizumab%2Dmrkz%20is,inhibits%20the%20IL%2D23%20pathway."},{"key":"2026013012042184244_j_jbcpp-2024-0102_ref_018","unstructured":"Drug, bank. [Home page in internet] Mirikizumab [Last cited on 22\/11\/2025] Available from: https:\/\/go.drugbank.com\/drugs\/DB14910."},{"key":"2026013012042184244_j_jbcpp-2024-0102_ref_019","unstructured":"European Medicines agency (EMA) [Home page in internet] Committee for Medicinal Products for Human Use (CHMP) Summary of Positive Opinion: Omvoh (mirikizumab) [Last cited on 22\/11\/2025] Available from: https:\/\/www.ema.europa.eu\/en\/documents\/smop-initial\/chmp-summary-positive-opinion-omvoh_en.pdf."},{"key":"2026013012042184244_j_jbcpp-2024-0102_ref_020","doi-asserted-by":"crossref","unstructured":"Steere, B, Beidler, C, Martin, A, Bright, S, Kikly, K, Benschop, RJ. Generation and characterization of mirikizumab, a humanized monoclonal antibody targeting the p19 subunit of IL-23. J\u00a0Pharmacol Exp Therapeut 2023;387:180\u20137. https:\/\/doi.org\/10.1124\/jpet.122.001512.","DOI":"10.1124\/jpet.122.001512"},{"key":"2026013012042184244_j_jbcpp-2024-0102_ref_021","doi-asserted-by":"crossref","unstructured":"Sands, BE, Peyrin-Biroulet, L, Kierkus, J, Higgins, PDR, Fischer, M, Jairath, V, et al.. Efficacy and safety of Mirikizumab in a randomized phase 2 study of patients with crohn\u2019s disease. Gastroenterology 2022;162:495\u2013508. https:\/\/doi.org\/10.1053\/j.gastro.2021.10.050.","DOI":"10.1053\/j.gastro.2021.10.050"},{"key":"2026013012042184244_j_jbcpp-2024-0102_ref_022","doi-asserted-by":"crossref","unstructured":"Sandborn, WJ, Ferrante, M, Bhandari, BR, Berliba, E, Hibi, T, D\u2019Haens, GR, et al.. Efficacy and safety of continued treatment with Mirikizumab in a phase 2 trial of patients with ulcerative colitis. Clin Gastroenterol Hepatol 2022;20:105\u201315.e14. https:\/\/doi.org\/10.1016\/j.cgh.2020.09.028.","DOI":"10.1016\/j.cgh.2020.09.028"},{"key":"2026013012042184244_j_jbcpp-2024-0102_ref_023","doi-asserted-by":"crossref","unstructured":"Sandborn, WJ, Ferrante, M, Bhandari, BR, Berliba, E, Feagan, BG, Hibi, T, et al.. Efficacy and safety of Mirikizumab in a randomized phase 2 study of patients with ulcerative colitis. Gastroenterology 2020;158:537\u201349.e10. https:\/\/doi.org\/10.1053\/j.gastro.2019.08.043.","DOI":"10.1053\/j.gastro.2019.08.043"},{"key":"2026013012042184244_j_jbcpp-2024-0102_ref_024","doi-asserted-by":"crossref","unstructured":"D\u2019Haens, G, Dubinsky, M, Kobayashi, T, Irving, PM, Howaldt, S, Pokrotnieks, J, LUCENT Study Group, et al.. Mirikizumab as induction and maintenance therapy for ulcerative colitis. N\u00a0Engl J Med 2023;388:2444\u201355. https:\/\/doi.org\/10.1056\/nejmoa2207940.","DOI":"10.1056\/NEJMoa2207940"},{"key":"2026013012042184244_j_jbcpp-2024-0102_ref_025","doi-asserted-by":"crossref","unstructured":"Steere, B, Schmitz, J, Powell, N, Higgs, R, Gottlieb, K, Liu, Y, et al.. Mirikizumab regulates genes involved in ulcerative colitis disease activity and anti-TNF resistance: results from a phase 2 study. Clin Transl Gastroenterol 2023;14:e00578. https:\/\/doi.org\/10.14309\/ctg.0000000000000578.","DOI":"10.14309\/ctg.0000000000000578"},{"key":"2026013012042184244_j_jbcpp-2024-0102_ref_026","doi-asserted-by":"crossref","unstructured":"Johnson, T, Steere, B, Zhang, P, Zang, Y, Higgs, R, Milch, C, et al.. Mirikizumab-induced transcriptome changes in ulcerative colitis patient biopsies at week 12 are maintained through week 52. Clin Transl Gastroenterol 2023;14:e00630. https:\/\/doi.org\/10.14309\/ctg.0000000000000630.","DOI":"10.14309\/ctg.0000000000000630"},{"key":"2026013012042184244_j_jbcpp-2024-0102_ref_027","doi-asserted-by":"crossref","unstructured":"Dubinsky, MC, Jairath, V, Feagan, BG, Naegeli, AN, Tuttle, J, Morris, N, et al.. Changes in health-related quality of life and associations with improvements in clinical efficacy: a phase 2 study of mirikizumab in patients with ulcerative colitis. BMJ Open Gastroenterol 2023;10:e001115. https:\/\/doi.org\/10.1136\/bmjgast-2023-001115.","DOI":"10.1136\/bmjgast-2023-001115"},{"key":"2026013012042184244_j_jbcpp-2024-0102_ref_028","doi-asserted-by":"crossref","unstructured":"Chua, L, Friedrich, S, Zhang, XC. Mirikizumab pharmacokinetics in patients with moderately to severely active ulcerative colitis: results from phase III LUCENT studies. Clin Pharmacokinet 2023;62:1479\u201391. https:\/\/doi.org\/10.1007\/s40262-023-01281-z.","DOI":"10.1007\/s40262-023-01281-z"},{"key":"2026013012042184244_j_jbcpp-2024-0102_ref_029","doi-asserted-by":"crossref","unstructured":"Dubinsky, MC, Clemow, DB, Hunter, GT, Li, X, Vermeire, S, Hisamatsu, T, et al.. Clinical effect of Mirikizumab treatment on bowel urgency in patients with moderately to severely active ulcerative colitis and the clinical relevance of bowel urgency improvement for disease remission. Crohns Colitis 2022;360:otac044.","DOI":"10.1093\/crocol\/otac044"}],"container-title":["Journal of Basic and Clinical Physiology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jbcpp-2024-0102\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jbcpp-2024-0102\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T12:04:44Z","timestamp":1769774684000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jbcpp-2024-0102\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,7,21]]},"published-print":{"date-parts":[[2026,2,2]]}},"alternative-id":["10.1515\/jbcpp-2024-0102"],"URL":"https:\/\/doi.org\/10.1515\/jbcpp-2024-0102","relation":{},"ISSN":["0792-6855","2191-0286"],"issn-type":[{"value":"0792-6855","type":"print"},{"value":"2191-0286","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]}}}